Hormone replacement therapy and cervical cancer: a systematic review of the literature

  title={Hormone replacement therapy and cervical cancer: a systematic review of the literature},
  author={Virginia Vargiu and Inbal Dona Amar and Andrea Rosati and Giorgia Dinoi and Luigi Carlo Turco and V A Capozzi and Giovanni Scambia and Paola Villa},
  pages={120 - 127}
Abstract Gynecological tumor treatment, including cervical cancer (CC) treatment, often leads to iatrogenic premature menopause. This highlights the critical importance of investigating indications for hormone replacement therapy (HRT), as most patients, thanks to the improvement in diagnosis and treatment, have to deal with the sequelae of their cancer treatments for many years. This systematic review aims to provide an overview of the current knowledge regarding the risks of HRT and CC. In… 
Hormone Replacement Therapy After Gynaecological Malignancies: a Review Article
This article is based on a selective literature search for relevant studies and guidelines regarding HRT after gynaecological malignancies and provides a broad overview of current research.
Risk of ovarian recurrence after ovarian conservation in early-stage cervical cancer treated with radical surgery: A propensity match analysis.
  • N. Bizzarri, L. Pedone Anchora, +9 authors G. Ferrandina
  • Medicine
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • 2021
CONSERV was associated with reduced risk of recurrence and menopausal symptoms in early-stage cervical cancer and should be considered in pre-menopausal women.
Menopausal hormone therapy in women with benign gynaecological conditions and cancer.
  • A. Brennan, M. Rees
  • Medicine
    Best practice & research. Clinical endocrinology & metabolism
  • 2021
It appears there is a small potential for symptom recurrence with menopausal hormone therapy use in menopausal women with a history of severe endometriosis, and the overall quality of data in this area is poor but suggestsWomen with a low risk of recurrence may consider hormonal therapy, balancing symptom impact with prognosis.
Hormone Replacement Therapy After Gynaecological Malignancies: a Review Article Hormonersatztherapie nach gynäkologischen Malignomen: eine Übersichtsarbeit
Bibliography Geburtsh Frauenheilk 2021; 81: 549–554 DOI 10.1055/a-1390-4353 ISSN 0016‐5751 © 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative
Association Between Hormone Replacement Therapy and Development of Endometrial Cancer: Results From a Prospective US Cohort Study
Although hormone replacement therapy (HRT) use is associated with elevated endometrial cancer(EC) risk, little evidence assesses potential effect-modifiers on HRT-related EC in a long-term follow-up.
MHT and Cancer


Hormone replacement therapy in gynecologic cancer survivors: why not?
In select women, it is reasonable to discuss and offer conventional HRT for the amelioration of menopausal symptoms and to improve quality of life.
Hormone replacement therapy after treatment for cervical cancer: Are we adhering to standard of care?
There is a need for clearer guidelines on HRT during survivorship and improved efforts to reduce disparities in the distribution of survivorship care.
Menopause, hormone replacement and gynaecological cancers
No study to date has found HRT to have a detrimental effect on survival in patients with early stage endometrial cancer, epithelial ovarian cancer, cervical cancer and vulval tumours, and HRT is only an absolute contraindication in low-grade endometricrial stromal sarcomas and is best avoided in granulosa cell ovarian tumours.
Hormone therapy after uterine cervical cancer treatment: a Swedish population–based study
Fewer than half of cervical cancer survivors with therapy-induced early menopause used HT at or close to the recommended dose, and the use decreased during follow-up.
Hormone replacement therapy and the risk of endometrial cancer: A systematic review.
Use of unopposed estrogen, tibolone and sequential combined therapy increases the risk of endometrial cancer, while considering both regimen and type of progestin.
Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix.
Exogenous estrogens, especially unopposed estrogen, were positively associated with adenocarcinomas and noncontraceptive hormones were negatively but weakly associated with squamous carcinomas.
Hormonal replacement therapy in ovarian cancer survivors: a survey among Greek gynecologists.
One out of two Greek gynecologists would prescribe HRT in ovarian cancer survivors, and an alternative therapy, mainly CNS medications, would be suggested by 21% of the opposers.
Hormone therapy for postmenopausal endometrial cancer survivors: a survey among Greek obstetricians-gynaecologists.
One out of three Greek gynaecologists would prescribe HRT to endometrial cancer survivors, and alternative therapies, mainly CNS medications, would be suggested by the opposers.
The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort
The results suggest that several hormonal factors are risk factors for cervical carcinogenesis and adherence to current cervical cancer screening guidelines should minimize the increased risk of CC associated with these hormonal risk factors.
Case-control study of oestrogen replacement therapy and risk of cervical cancer
It is suggested that exogenous oestrogens do not increase the risk of cervical cancer and may decrease the risk, and the reduced risk seems to persist for 10 years or more.